National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Risdiplam (Evrysdi™). HTA ID: 21006

Risdiplam (Evrysdi™) is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.

 

NCPE Assessment Process Complete
Rapid review commissioned 15/03/2021
Rapid review completed 29/03/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of risdiplam compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 04/05/2021
Pre-submission consultation with Applicant 28/06/2021
Full HTA submission received from Applicant 20/08/2021
Preliminary review sent to Applicant 01/10/2021
NCPE assessment re-commenced 29/10/2021
Preliminary review follow-up sent to Applicant 26/11/2021
NCPE assessment re-commenced 20/12/2021
Factual accuracy check sent to Applicant 18/02/2022
NCPE assessment re-commenced 25/02/2022
NCPE assessment completed 31/03/2022
NCPE assessment outcome The NCPE recommends that risdiplam not be considered for reimbursement until cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.